TABLE 2

Study clinical endpoints

Variables	Placebo	Aganirsen (0.86 mg/g)	Aganirsen (1.72 mg/g)
% Evolution in lesion area (visit 3)^{^a}	24.5 ± 41.7	−14.4 ± 38.6^*	−12.9 ± 52.4^*
% Evolution in lesion area (visit 2)	18.5 ± 30.9	−18.8 ± 28.4**	−19.8 ± 31.4**
TSS score^{^b}
Baseline	5.5 ± 1.0	5.7 ± 1.5	5.5 ± 1.2
6 weeks	3.4 ± 1.2	3.6 ± 1.9	3.2 ± 1.3
PGA^{^c}
Baseline	2.5 ± 0.7	2.5 ± 0.8	2.5 ± 0.7
6 weeks	3.7 ± 1.1	3.7 ± 1.2	3.9 ± 1.0
Tolerance^{^d}
Pruritus baseline	0.3 ± 0.6	0.3 ± 0.6	0.3 ± 0.6
6 weeks	0.2 ± 0.6	0.2 ± 0.6	0.2 ± 0.6
Change in irritation	0 ± 0	0 ± 0	0 ± 0
Change in burning	0 ± 0	0 ± 0	0 ± 0
Change in exudation	0 ± 0	0 ± 0	0 ± 0
Change in itching after 6 weeks
−1	1 (8.3%)	1 (8.3%)	1 (8.3%)
0	10 (83.3%)	10 (83.3%)	10 (83.3%)
2	1 (8.3%)	1 (8.3%)	1 (8.3%)

↵a Percentage evolution (mean ± S.D.) between week 6 (visit 3) and week 3 (visit 2) and baseline (visit 1) in area of treated psoriasis plaque as measured by photography; two types of diameters were measured, both at baseline, 3 weeks, and 6 weeks after treatment: sum of diameters (mm) from the Case Report Form and diameters (cm) as measured on pictures.
↵b TSS: sum of signs (redness/erythema, scale/crusting, thickening/elevation) and symptoms (pruritus) using 4-point scales (e.g., none/clear = 0, mild = 1, moderate = 2, extensive = 3). Score varies from 0 to 12 for each lesion.
↵c For PGA, three items were noted: erythema, induration, and scale, according to Feldman and Krueger (2005).
↵d Local tolerance of treatment: patient’s assessment on a 4-point scale of irritation, itching, pruritus, sensation of burning, and exudation.
↵* P < 0.05 vs. placebo; **P < 0.01 vs. placebo.